Skip to content

US · TMO · MEDICAL - DIAGNOSTICS & RESEARCH

Thermo Fisher Scientific Inc. (TMO) intrinsic value and stock valuation

$669.54as of 2026-11-21 · Mkt cap 220.74B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Thermo Fisher Scientific Inc. DCF and intrinsic value

InvestorsCraft values TMO with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from TMO’s statements →

Thermo Fisher Scientific Inc. Graham Number

Graham Number: $239.59d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Waltham, MA 02451 thermofisher.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$44.6B+6.7% 5y CAGRd
20112025
Net income
$6.74B+1.1% 5y CAGRd
20112025
Free cash flow
$6.29B-1.6% 5y CAGRd
20112025
Total equity
$53.5B+9.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$44.6B$42.9B$42.9B$44.9B$39.2B
Operating income$8.11B$7.66B$7.45B$8.53B$10.3B
Net income$6.74B$6.34B$6B$6.95B$7.73B
EPSd$17.9M$16.5M$15.5M$17.6M$19.5M
Operating cash flow$7.82B$8.67B$8.41B$9.15B$9.54B
Capital expenditure-$-1.53B-$-1.4B-$-1.48B-$-2.24B-$-2.52B
Free cash flow$6.29B$7.27B$6.93B$6.91B$7.02B
Total assets$110.3B$97.3B$98.7B$97.2B$95.1B
Total debt$39.4B$32.8B$36.4B$36.1B$36.3B
Net debt$29.5B$28.8B$28.3B$27.5B$31.9B
Total equity$53.5B$49.7B$46.8B$44.1B$41B
Cash and short-term investments$10.1B$5.58B$8.08B$8.52B$4.48B
Income statement
20252024202320222021
Revenue$44.6B$42.9B$42.9B$44.9B$39.2B
Cost of revenue$27.8B$25.2B$25.7B$25.9B$19.6B
Gross profit$16.8B$17.7B$17.2B$19B$19.6B
Research and development expenses$1.4B$1.39B$1.34B$1.47B$1.41B
Selling, general and administrative expenses$7.27B$8.68B$8.41B$9.02B$7.91B
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$8.67B$10.1B$9.75B$10.5B$9.32B
Cost and expenses$36.4B$35.2B$35.4B$36.4B$28.9B
Interest income$993M$1.08B$879M$272M$43M
Interest expense$1.42B$1.65B$1.49B$726M$536M
Depreciation and amortization$2.78B$3.11B$3.41B$3.38B$2.59B
Ebitda$11.5B$11.8B$11.2B$11.9B$12B
Operating income$8.11B$7.66B$7.45B$8.53B$10.3B
Total other income/expenses, net-$-842M-$-667M-$-1.21B-$-862M-$-1.48B
Income before tax$7.27B$7B$6.24B$7.66B$8.84B
Income tax expense$547M$657M$284M$703M$1.11B
Net income$6.74B$6.34B$6B$6.95B$7.73B
Weighted average shares outstanding$376M$382M$386M$392M$394M
Weighted average diluted shares outstanding$377M$383M$388M$394M$397M
Balance sheet
20252024202320222021
Cash and short-term investments$10.1B$5.58B$8.08B$8.52B$4.48B
Net receivables$10.6B$9.63B$9.66B$9.43B$8.95B
Inventory$5.43B$4.98B$5.09B$5.63B$5.05B
Total current assets$28.7B$22.1B$24.6B$25.2B$20.1B
Property, plant and equipment, net$10.6B$10.8B$11B$10.9B$9.86B
Goodwill and intangible assets$65.2B$61.4B$60.7B$58.7B$62.1B
Long-term investments$0.00$560M$59M$155M$73M
Total non-current assets$81.6B$75.2B$74.1B$71.9B$75B
Total assets$110.3B$97.3B$98.7B$97.2B$95.1B
Accounts payable$3.62B$3.08B$2.87B$3.38B$2.87B
Short-term debt$3.53B$2.48B$3.87B$5.85B$2.8B
Deferred revenue$2.71B$2.85B$2.69B$2.6B$2.66B
Total current liabilities$15.2B$13.3B$14B$17B$13.4B
Long-term debt$35.9B$30.3B$32.6B$30.2B$33.5B
Deferred revenue, non-current$0.00$1.14B$1.5B$1.18B$1.24B
Total non-current liabilities$41.6B$34.3B$37.9B$36B$40.7B
Capital lease obligations$0.00$1.24B$1.24B$1.31B$1.39B
Total liabilities$56.8B$47.7B$51.9B$53B$54.1B
Common stock$445M$444M$442M$441M$439M
Retained earnings$59.2B$53.1B$47.4B$41.9B$35.4B
Accumulated other comprehensive income (loss)-$-2.45B-$-2.7B-$-3.22B-$-3.1B-$-2.33B
Total equity$53.5B$49.7B$46.8B$44.1B$41B
Total investments$253M$2.12B$59M$155M$73M
Total debt$39.4B$32.8B$36.4B$36.1B$36.3B
Net debt$29.5B$28.8B$28.3B$27.5B$31.9B
Cash flow statement
20252024202320222021
Net income$6.72B$6.34B$6B$6.96B$7.73B
Depreciation and amortization$2.78B$3.11B$3.41B$3.38B$2.59B
Stock-based compensation$310M$301M$278M$307M$230M
Change in working capital-$-1.77B-$-334M-$-537M-$-1.05B-$-1.56B
Accounts receivable-$-426M-$-171M$209M-$-430M-$-204M
Inventory-$-74M-$-27M$598M-$-825M-$-1.07B
Accounts payable$421M$212M-$-500M$648M$479M
Net cash provided by operating activities$7.82B$8.67B$8.41B$9.15B$9.54B
Investments in property, plant and equipment-$-1.53B-$-1.4B-$-1.48B-$-2.24B-$-2.52B
Acquisitions, net-$-4.04B-$-3.13B-$-3.66B-$-39M-$-19.4B
Net cash used for investing activities-$-4.05B-$-5.84B-$-5.14B-$-2.16B-$-21.93B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-3B-$-4B-$-3B-$-3B-$-2B
Dividends paid-$-636M-$-583M-$-523M-$-455M-$-395M
Net cash used for financing activities$1.8B-$-6.79B-$-3.62B-$-2.81B$6.58B
Net change in cash$5.84B-$-4.06B-$-440M$4.05B-$-5.85B
Cash at end of period$9.88B$4.04B$8.1B$8.54B$4.49B
Operating cash flow$7.82B$8.67B$8.41B$9.15B$9.54B
Capital expenditure-$-1.53B-$-1.4B-$-1.48B-$-2.24B-$-2.52B
Free cash flow$6.29B$7.27B$6.93B$6.91B$7.02B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Thermo Fisher Scientific Inc.

        Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

        CEO
        Marc N. Casper
        Employees
        125K
        Beta
        0.87

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Thermo Fisher Scientific Inc. (TMO)?

        Thermo Fisher Scientific Inc. (TMO) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TMO undervalued?

        TMO trades at a price of $669.54 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.